sr9009
METABOLIC · REV-ERB AGONIST · NON-ANDROGENIC · T½ NOT ESTABLISHED IN HUMANS
also: stenabolic · SR-9009
SR9009 is a synthetic REV-ERB agonist whose reputation rests on a single influential 2012 Nature study in mice reporting increased energy expenditure and reduced fat mass. No human trial has been published, and subsequent knockout work demonstrated that its cellular effects occur independently of REV-ERB, meaning the mechanism attributed to it does not explain what it actually does.
// our evidence grade — unedited
There are no human trials at all, and a 2019 PNAS study using REV-ERB double-knockout cells showed SR9009 retains its effects without its supposed target, undermining the mechanistic premise on which the entire rodent literature was interpreted.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | SR9009 (stenabolic) |
| cas | 1379686-30-2 |
| formula | C20H24ClN3O4S |
| molar mass | 437.9 g/mol |
| purity | ≥ 98% HPLC |
| form | research solution |
| storage | Reference material: store as a solid, desiccated and protected from light, at -20 °C for long-term stability; stock solutions typically stored at -80 °C with freeze-thaw cycles minimised. |
| solubility | Lipophilic small molecule; soluble in DMSO and ethanol, poorly soluble in aqueous buffer. Lot-specific solubility should be taken from the certificate of analysis. |
// select size
crypto payment · research use only · not for human consumption
// others in Anabolic & Receptor